大会生物科学的HBV组合进展会议电话PDF

newchinabok

https://investor.assemblybio.com ... ess-conference-call

newchinabok

Supporting Materials

Assembly Biosciences HBV Portfolio Progress Presentation 702.2 KB

newchinabok

请下载PDF观看

newchinabok

在研乙肝新药ABI-H0731启动Phase 2a 期临床试验
2018-07-10来源：一诺医学作者：略晓薛
Assembly Biosciences 公司近日宣布，正式启动公司在研乙肝新药 ABI-H0731 用于慢乙肝治疗的两项 Phase 2a 期多中心，随机，安慰剂对照临床试验。

newchinabok

2018年7月启动abi—h0731，二期。至今过去了二年，到了停药观察阶段了

乙肝人1949

关键是截止目前的试验数据呢?

乙肝人1949

有最新最全的数据吗?

newchinabok

乙肝人1949 发表于 2020-5-18 22:26
有最新最全的数据吗?

八月欧肝会有数据，（pdf15有预告）请关注

newchinabok

EASL 2020/The Digital International Liver Congress (Aug 27-29):
4 Abstracts Accepted for Presentation

newchinabok

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered
with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive
chronic hepatitis B infection in a long-term extension study
Lead Author: Man-Fung Yuen
Abstracts expected to publish online ~August 20, 2020 10:00 am CET
Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731
administered with a nucleos(t)ide reverse transcriptase inhibitor in patients
with HBeAg-negative chronic hepatitis B infection
Lead Author: Scott Fung
Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B
core inhibitor ABI-H2158 in a Phase 1b study of patients with HBeAg-positive
chronic hepatitis B infection
Lead Author: Kosh Agarwal
Development of a Highly Sensitive Multiplex Platform Assay to Monitor Low Levels
of HBV DNA and pgRNA in Samples from Patients with Chronic Hepatitis B
Lead Author: Qi Huang